Phase I
Spark Therapeutics, with its partner Pfizer, published interim data from its Phase I/II clinical trial of a gene therapy for hemophilia B in The New England Journal of Medicine.
Nobody is interested in slow-growth or no-growth stocks, long term or short term, but everyone’s interested in fast-growing stocks.
With the $63.5B takeover of Monsanto by Bayer taking longer than expected, and a key patent for Xarelto expiring in 2024, Bayer’s execs are finding themselves defending their decisions.
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
As the world watches big pharma companies take on the challenges of developing a viable therapy for ALZ’s disease, smaller companies are also attempting to blaze a treatment trail in the neurodegenerative market.
Instead of targeting a molecule called CD19 on the surface of the cancer cells, the new therapy targets a molecule called CD22.
Researchers are making great headway against cancer, even though it’s currently still the second-leading cause of death in the U.S.
CAR-T is a hot new area and there are companies hot on Gilead’s tail, namely Juno, in a partnership with Celgene, and Novartis.
Moderna announced that it has dosed its first patient in a Phase I trial of mRNA-4157, a mRNA-based personalized cancer vaccine.
Barely a week after announcing it was moving into a new corporate headquarters, Sangamo announced it has dosed the first patient in its Phase I/II gene therapy trial.
PRESS RELEASES